- Home
- MSD vs BMEA Comparison
MSD vs BMEA Comparison
Compare MSD & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSD
- BMEA
- Stock Information
- Founded
- MSD 1993
- BMEA 2017
- Country
- MSD United States
- BMEA United States
- Employees
- MSD N/A
- BMEA N/A
- Industry
- MSD Trusts Except Educational Religious and Charitable
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- MSD Finance
- BMEA Health Care
- Exchange
- MSD Nasdaq
- BMEA Nasdaq
- Market Cap
- MSD 154.7M
- BMEA 125.0M
- IPO Year
- MSD N/A
- BMEA 2021
- Fundamental
- Price
- MSD $7.39
- BMEA $1.36
- Analyst Decision
- MSD
- BMEA Strong Buy
- Analyst Count
- MSD 0
- BMEA 8
- Target Price
- MSD N/A
- BMEA $10.63
- AVG Volume (30 Days)
- MSD 70.2K
- BMEA 3.9M
- Earning Date
- MSD 01-01-0001
- BMEA 10-29-2025
- Dividend Yield
- MSD 11.26%
- BMEA N/A
- EPS Growth
- MSD N/A
- BMEA N/A
- EPS
- MSD N/A
- BMEA N/A
- Revenue
- MSD N/A
- BMEA N/A
- Revenue This Year
- MSD N/A
- BMEA N/A
- Revenue Next Year
- MSD N/A
- BMEA N/A
- P/E Ratio
- MSD N/A
- BMEA N/A
- Revenue Growth
- MSD N/A
- BMEA N/A
- 52 Week Low
- MSD $6.11
- BMEA $1.29
- 52 Week High
- MSD $7.46
- BMEA $10.80
- Technical
- Relative Strength Index (RSI)
- MSD 47.79
- BMEA 37.25
- Support Level
- MSD $7.22
- BMEA $1.34
- Resistance Level
- MSD $7.51
- BMEA $1.50
- Average True Range (ATR)
- MSD 0.08
- BMEA 0.10
- MACD
- MSD 0.01
- BMEA -0.02
- Stochastic Oscillator
- MSD 58.62
- BMEA 12.50
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.